Cara Community Biotechs: Novavax

Novavax (NASDAQ: NVAX) reviewed 10-14-2020

Market Cap: $7.23 Billion (USD)                 Share Price: $118.00 (USD)

Shares outstanding: 61,262,632 as of 30 Jun 2020

Cash & cash equivalents: $424,395 M (USD) as of 30 Jun 2020

Debt:     $323,321 M (USD) via Convertible notes

Insiders: Low      Institutional: 36 holders own approx. 14%

Website: novavax.com

Investor Presentations:  https://novavax.com/resources#presentations

CEO: Stanley C. Erck         HQs: Gaithersburg, MD, USA

Novavax is a phase 2 & 3-stage biotech with vaccines to prevent infectious RSV disease in infants and seasonal flu in adults as well as some of the world’s toughest viruses

The vaccine technology combines genetic engineering with the immunogenicity enhancing properties of the company’s proprietary Matrix-M adjuvant

R&D pipeline includes vaccines in various phases of development to address these viruses:

  • NVX-CoV2373 – Coronavirus – Phase 1
  • Nanoflu – Influenza – Phase 3
  • Resvax-RSV F Vaccine (Infants) – Respiratory Syncytial Virus (RSV) – Phase 3
  • RSV F Vaccine (adults) – Phase 2
  • RSV-F Vaccine (Pediatrics) – Phase 1
  • Ebola GP Vaccine – Phase 1
  • MERS – Pre-clinical phase
  • SARS – Pre-clinical phase
  • Seasonal flu (Age: 60+) – Pre-clinical phase

Bottom line:

  • As an mRNA alternative, their DNA approach might become an industry leader

Like to give your opinion? Join our Community Discussion